Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Thought Leaders

- PMLiVE

Countries hail ‘landmark’ drug pricing transparency resolution, despite watering down

US among those in favour of price transparency

- PMLiVE

Huntsworth bolsters market access capabilities with Creativ-Ceutical

Adds new capabilities and global presence

- PMLiVE

Europe responding to gene therapy challenge, but picture remains fragmented

Germany, Italy and England using outcomes-based deals

- PMLiVE

Vertex chief Jeffrey Leiden to weigh in on Orkambi inquiry

Will be joined by chief commercial officer Stuart Arbuckle

- PMLiVE

‘Inflexible’ NICE blocking access to rare disease drugs

Spinraza most high profile example of access problem

- PMLiVE

Industry concerned about ‘rushed’ Brexit withdrawal legislation

The Patents Amendment could weaken the UK’s IP framework, warns biopharma

- PMLiVE

NICE and Canadian counterpart to offer joint advice service

Agencies offer parallel scientific advice

- PMLiVE

Beneluxa: the future of European market access?

Andrew McConaghie talks to Beneluxa’s Marcel van Raaij and Biogen’s Erik Smet about their groundbreaking deal on Spinraza and what it means for European market access

- PMLiVE

Digital applications are transforming the market access landscape

Optimising product value through digital technology

Comment: the new UK pricing deal – welcome news, but lessons to be learned

Leslie Galloway, chairman of EMIG reflects on the new UK government-pharma industry pricing agreement

- PMLiVE

New ‘voluntary’ UK pricing deal caps growth, but promises faster uptake

Decades old PPRS name to go

The European Medicines Agency: PRIME’d for access?

Leela Barham examines the impact of the EMA's PRIME fast track system after two years

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links